Inherited Neuropathies

Jun Li

doi:10.1055/s-0032-1329198

Seminars in Neurology, Table of Contents

Semin Neurol 2012; 32(03): 204-214
DOI: 10.1055/s-0032-1329198

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Inherited Neuropathies

Jun Li

¹Department of Neurology, Center for Molecular Neuroscience, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee

› Author Affiliations

Abstract

With a prevalence of 1 in 2500 people, inherited peripheral nerve diseases, collectively called Charcot-Marie-Tooth disease (CMT), are among the most common inherited neurologic disorders. Patients with CMT typically present with chronic muscle weakness and atrophy in limbs, sensory loss in the feet and hands, and foot deformities. Clinical similarities between patients often require genetic testing to achieve a precise diagnosis. In this article, the author reviews the clinical and pathologic features of CMT, and demonstrates how electrodiagnostic and genetic tools are used to assist in the diagnosis and symptomatic management of the diseases. Several cases are presented to illustrate the diagnostic processes.

Keywords

Charcot-Marie-Tooth disease - neuropathy - dysmyelination - demyelination - axonal degeneration - nerve conduction study - sural nerve biopsy - PMP22 - MPZ - mitofusin-2 - genetics - DNA testing

Full Text

References

References
1 Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968; 18 (6) 603-618
2 Thomas PK, Marques Jr W, Davis MB , et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997; 120 (Pt 3) 465-478
3 Krajewski KM, Lewis RA, Fuerst DR , et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000; 123 (Pt 7) 1516-1527
4 Roussy G, Levy G. Sept cas d'une maladie familiale particuliere. Rev Neurol 1926; 45: 427-450
5 Shy ME, Jáni A, Krajewski K , et al. Phenotypic clustering in MPZ mutations. Brain 2004; 127 (Pt 2) 371-384
6 Li J, Bai YH, Ianakova E , et al. Major myelin protein gene (P0) mutation causes a novel form of axonal degeneration. J Comp Neurol 2006; 498 (2) 252-265
7 Bai YH, Ianokova E, Pu Q , et al. R69C Mutation in P0 gene alters myelination and ion channel subtypes. Arch Neurol 2006; 63: 1787-1794
8 Street VA, Bennett CL, Goldy JD , et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003; 60 (1) 22-26
9 Lupski JR, de Oca-Luna RM, Slaugenhaupt S , et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991; 66 (2) 219-232
10 Raeymaekers P, Timmerman V, Nelis E , et al; HMSN Collaborative Research Group. Estimation of the size of the chromosome 17p11.2 duplication in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). J Med Genet 1992; 29 (1) 5-11
11 Chance PF, Alderson MK, Leppig KA , et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993; 72 (1) 143-151
12 Parmantier E, Cabon F, Braun C, D'Urso D, Müller HW, Zalc B. Peripheral myelin protein-22 is expressed in rat and mouse brain and spinal cord motoneurons. Eur J Neurosci 1995; 7 (5) 1080-1088
13 Parmantier E, Braun C, Thomas JL, Peyron F, Martinez S, Zalc B. PMP-22 expression in the central nervous system of the embryonic mouse defines potential transverse segments and longitudinal columns. J Comp Neurol 1997; 378 (2) 159-172
14 Snipes GJ, Suter U, Welcher AA, Shooter EM. Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). J Cell Biol 1992; 117 (1) 225-238
15 Gouider R, LeGuern E, Gugenheim M , et al. Clinical, electrophysiologic, and molecular correlations in 13 families with hereditary neuropathy with liability to pressure palsies and a chromosome 17p11.2 deletion. Neurology 1995; 45 (11) 2018-2023
16 Vallat JM, Sindou P, Preux PM , et al. Ultrastructural PMP22 expression in inherited demyelinating neuropathies. Ann Neurol 1996; 39 (6) 813-817
17 Li J, Bai Y, Ghandour K , et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 2005; 128 (Pt 5) 1168-1177
18 Katona I, Wu X, Feely SM , et al. PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain 2009; 132 (Pt 7) 1734-1740
19 Nicholson GA, Valentijn LJ, Cherryson AK , et al. A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies. Nat Genet 1994; 6 (3) 263-266
20 Li J, Ghandour K, Radovanovic D , et al. Stoichiometric alteration of PMP22 protein determines the phenotype of HNPP. Arch Neurol 2007; 64: 974-978
21 Sabéran-Djoneidi D, Sanguedolce V, Assouline Z, Lévy N, Passage E, Fontés M. Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. Gene 2000; 248 (1–2) 223-231
22 Passage E, Norreel JC, Noack-Fraissignes P , et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10 (4) 396-401
23 Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9 (12) 1533-1537
24 Pareyson D, Schenone A, Fabrizi GM , et al; CMT-TRIAAL Group. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. [EudraCT no.: 2006–000032–27] Pharmacol Res 2006; 54 (6) 436-441
25 Pareyson D, Reilly MM, Schenone A , et al; CMT-TRIAAL; CMT-TRAUK groups. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011; 10 (4) 320-328
26 Hayasaka K, Takada G, Ionasescu VV. Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type 1B. Hum Mol Genet 1993; 2 (9) 1369-1372
27 Martini R, Mohajeri MH, Kasper S, Giese KP, Schachner M. Mice doubly deficient in the genes for P0 and myelin basic protein show that both proteins contribute to the formation of the major dense line in peripheral nerve myelin. J Neurosci 1995; 15 (6) 4488-4495
28 Pennuto M, Tinelli E, Malaguti M , et al. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 2008; 57 (3) 393-405
29 Warner LE, Mancias P, Butler IJ , et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998; 18 (4) 382-384
30 Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982; 32 (6) 592-596
31 Gutierrez A, England JD, Sumner AJ , et al. Unusual electrophysiological findings in X-linked dominant Charcot-Marie-Tooth disease. Muscle Nerve 2000; 23 (2) 182-188
32 Gabreëls-Festen A, Wetering RV. Human nerve pathology caused by different mutational mechanisms of the PMP22 gene. Ann N Y Acad Sci 1999; 883: 336-343
33 Krajewski K, Turansky C, Lewis R , et al. Correlation between weakness and axonal loss in patients with CMT1A. Ann N Y Acad Sci 1999; 883: 490-492
34 Bergoffen J, Scherer SS, Wang S , et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262 (5142) 2039-2042
35 Reilly MM, Shy ME. Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry 2009; 80 (12) 1304-1314
36 Balice-Gordon RJ, Bone LJ, Scherer SS. Functional gap junctions in the Schwann cell myelin sheath. J Cell Biol 1998; 142 (4) 1095-1104
37 Tabaraud F, Lagrange E, Sindou P, Vandenberghe A, Levy N, Vallat JM. Demyelinating X-linked Charcot-Marie-Tooth disease: unusual electrophysiological findings. Muscle Nerve 1999; 22 (10) 1442-1447
38 Hahn AF, Ainsworth PJ, Bolton CF, Bilbao JM, Vallat JM. Pathological findings in the X-linked form of Charcot-Marie-Tooth disease: a morphometric and ultrastructural analysis. Acta Neuropathol 2001; 101 (2) 129-139
39 Saporta MA, Katona I, Zhang X , et al. Neuropathy in a human without the PMP22 gene. Arch Neurol 2011; 68 (6) 814-821
40 Li J, Krajewski K, Lewis RA, Shy ME. Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies. Muscle Nerve 2004; 29 (2) 205-210
41 Horowitz SH, Spollen LE, Yu W. Hereditary neuropathy with liability to pressure palsy: fulminant development with axonal loss during military training. J Neurol Neurosurg Psychiatry 2004; 75 (11) 1629-1631
42 Madrid R, Bradley G. The pathology of neuropathies with focal thickening of the myelin sheath (tomaculous neuropathy): studies on the formation of the abnormal myelin sheath. J Neurol Sci 1975; 25: 415-448
43 Bai Y, Zhang X, Katona I , et al. Conduction block in PMP22 deficiency. J Neurosci 2010; 30 (2) 600-608
44 Li J, Krajewski K, Shy ME, Lewis RA. Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name. Neurology 2002; 58 (12) 1769-1773
45 Lewis RA, Sumner AJ, Shy ME. Electrophysiological features of inherited demyelinating neuropathies: A reappraisal in the era of molecular diagnosis. Muscle Nerve 2000; 23 (10) 1472-1487
46 Züchner S, Mersiyanova IV, Muglia M , et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36 (5) 449-451
47 Chen H, Chan DC. Critical dependence of neurons on mitochondrial dynamics. Curr Opin Cell Biol 2006; 18 (4) 453-459
48 Deng HX, Klein CJ, Yan J , et al. Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat Genet 2010; 42 (2) 165-169
49 Verhoeven K, De Jonghe P, Coen K , et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003; 72 (3) 722-727
50 Antonellis A, Ellsworth RE, Sambuughin N , et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003; 72 (5) 1293-1299
51 Sivakumar K, Kyriakides T, Puls I , et al. Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain 2005; 128 (Pt 10) 2304-2314
52 Evgrafov OV, Mersiyanova I, Irobi J , et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 2004; 36 (6) 602-606
53 Irobi J, Van Impe K, Seeman P , et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet 2004; 36 (6) 597-601
54 Mersiyanova IV, Ismailov SM, Polyakov AV , et al. Screening for mutations in the peripheral myelin genes PMP22, MPZ and Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients. Hum Mutat 2000; 15 (4) 340-347
55 Bolis A, Zordan P, Coviello S, Bolino A. Myotubularin-related (MTMR) phospholipid phosphatase proteins in the peripheral nervous system. Mol Neurobiol 2007; 35 (3) 308-316
56 Bolino A, Bolis A, Previtali SC , et al. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J Cell Biol 2004; 167 (4) 711-721
57 Bolis A, Coviello S, Bussini S , et al. Loss of Mtmr2 phosphatase in Schwann cells but not in motor neurons causes Charcot-Marie-Tooth type 4B1 neuropathy with myelin outfoldings. J Neurosci 2005; 25 (37) 8567-8577
58 Chow CY, Zhang Y, Dowling JJ , et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007; 448 (7149) 68-72
59 Zhang X, Chow CY, Sahenk Z, Shy ME, Meisler MH, Li J. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain 2008; 131 (Pt 8) 1990-2001
60 Nicholson G, Lenk GM, Reddel SW , et al. Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P₂ phosphatase FIG4. Brain 2011; 134 (Pt 7) 1959-1971
61 Boerkoel CF, Takashima H, Stankiewicz P , et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet 2001; 68 (2) 325-333
62 Bomont P, Cavalier L, Blondeau F , et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet 2000; 26 (3) 370-374
63 Chance PF, Lensch MW, Lipe H, Brown Sr RH, Brown Jr RH, Bird TD. Hereditary neuralgic amyotrophy and hereditary neuropathy with liability to pressure palsies: two distinct genetic disorders. Neurology 1994; 44 (12) 2253-2257
64 Kuhlenbäumer G, Hannibal MC, Nelis E , et al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat Genet 2005; 37 (10) 1044-1046
65 Houlden H, King R, Blake J , et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 2006; 129 (Pt 2) 411-425
66 Toyooka K. Fabry disease. Curr Opin Neurol 2011; 24 (5) 463-468
67 England JD, Gronseth GS, Franklin G , et al; American Academy of Neurology. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72 (2) 185-192
68 Patzkó A, Shy ME. Update on Charcot-Marie-Tooth disease. Curr Neurol Neurosci Rep 2011; 11 (1) 78-88
69 Reilly MM, Shy ME. Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry 2009; 80 (12) 1304-1314
70 Lupski JR, Reid JG, Gonzaga-Jauregui C , et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362 (13) 1181-1191
71 Garofalo K, Penno A, Schmidt BP , et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest 2011; 121 (12) 4735-4745
72 Schaefer RM, Tylki-Szymańska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 2009; 69 (16) 2179-2205
73 Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996; 77 (7) 1356-1362